SCHEMBL5787969

SCHEMBL5787969

C=C(C)Cc1cccc(OC)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.56
ALOX5 P09917 1/20 0.54
PTGS2 P35354 1/20 0.54
MAPT P10636 6/20 0.52
ALDH1A1 P00352 5/20 0.52
KDM4E B2RXH2 3/20 0.52
HPGD P15428 3/20 0.52
CYP3A4 P08684 2/20 0.52
ALOX15 P16050 2/20 0.52
LMNA P02545 2/20 0.52
ALOX12 P18054 2/20 0.52
TP53 P04637 1/20 0.52
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CALM1 P0DP23 1/20 0.51
GAA P10253 7/20 0.48
GFER P55789 1/20 0.48
TLR2 O60603 1/20 0.47
ERN1 O75460 1/20 0.47
TLR1 Q15399 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5719348 0.83 LMNA (0.56) IDO1MAPTALDH1A1CYP3A4LMNA
SCHEMBL5783356 0.83 MEN1 (0.41) IDO1ALOX5PTGS2MAPTALDH1A1
SCHEMBL11061615 0.82 GABRA1 (0.52) IDO1MAPTALDH1A1HPGDALOX15
SCHEMBL28235226 0.82 IDO1 (0.60) IDO1ALOX5PTGS2MAPTALDH1A1
SCHEMBL2874758 0.79 IDO1 (0.56) IDO1ALOX5PTGS2MAPTALDH1A1
SCHEMBL5786427 0.78 ALOX5 (0.54) IDO1ALOX5PTGS2MAPTALDH1A1
SCHEMBL5786238 0.78 SMN1; SMN2 (0.44) IDO1MAPTALDH1A1KDM4EALOX15
SCHEMBL5786432 0.78 ALOX5 (0.54) IDO1ALOX5PTGS2MAPTALDH1A1
SCHEMBL10735838 0.78 EGFR (0.39) IDO1LMNAHTR2AHTR2CTAAR1
SCHEMBL8389267 0.77 IAPP (0.52) MAPTALDH1A1KDM4EHPGDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270577-B1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-12-06 EP disclosed
US-6924292-B2 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 US disclosed
EP-1270577-A1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof PDE3B, PDE5A, PDE3A IDO1 410/4885ALOX5 287/4885PTGS2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.